Addex Therapeutics (FRA:APE) Beginning Cash Position: €1.80 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Addex Therapeutics Beginning Cash Position?

Addex Therapeutics FRA:APE Beginning Cash Position is €1.80 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Addex Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was €1.80 Mil.

Addex Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 (€2.53 Mil) to Dec. 2025 (€2.34 Mil) and declined from Dec. 2025 (€2.34 Mil) to Mar. 2026 (€1.80 Mil).

Addex Therapeutics's annual Beginning Cash Position declined from Dec. 2023 (€7.38 Mil) to Dec. 2024 (€4.14 Mil) and declined from Dec. 2024 (€4.14 Mil) to Dec. 2025 (€3.58 Mil).

Addex Therapeutics Beginning Cash Position Related Terms

Addex Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Beginning Cash Position Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.96 20.76 7.38 4.14 3.58

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.50 2.23 2.53 2.34 1.80

Addex Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €1.80 Mil mean?
Addex Therapeutics (FRA:APE) has a Beginning Cash Position of €1.80 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Addex Therapeutics and its competitors.
Is Addex Therapeutics' Beginning Cash Position too high?
Addex Therapeutics' current Beginning Cash Position is €1.80 Mil.
How does Addex Therapeutics' Beginning Cash Position compare to VRTX and REGN?
Addex Therapeutics' Beginning Cash Position of €1.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Addex Therapeutics and its competitors. Addex Therapeutics's current Beginning Cash Position is €1.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE) has a current Beginning Cash Position of €1.80 Mil. The stock's GF Value™ is €0.01, compared to a current price of €0.04 — trading 310% above its estimated fair value. The current Beginning Cash Position is €1.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current Beginning Cash Position is €1.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.